Main Logo

Martin Dietrich, MD, PhD

Articles by Martin Dietrich, MD, PhD

Millie Das, MDExpert Interviews | July 29, 2025
In the final segment of the roundtable discussion, the panel reflects on pressing unanswered questions in lung cancer.
View More
Millie Das, MDExpert Interviews | July 29, 2025
In the fourth segment of this roundtable discussion, the panel weighs in on the most pressing unmet needs in NSCLC.
Millie Das, MDExpert Interviews | July 29, 2025
In the third segment of this roundtable discussion, the panel discusses considerations for community oncologists.
Millie Das, MDExpert Interviews | July 29, 2025
In the second segment of this roundtable discussion, the panel discusses the molecular testing landscape in NSCLC.
Millie Das, MDExpert Interviews | July 29, 2025
In the first segment of this roundtable discussion, the panel explores the rising incidence of young-onset lung cancer.
Millie Das, MDASCO 2024 | August 6, 2024
Experts weigh in on the long-term results presented at the 2024 American Society of Clinical Oncology Annual Meeting.
Millie Das, MDASCO 2024 | August 6, 2024
The panel discusses key questions about NSCLC treatment regimens and the research that could answer them.
Millie Das, MDASCO 2024 | August 6, 2024
Experts discuss important management considerations and the importance of working with a multidisciplinary team.
Millie Das, MDASCO 2024 | August 6, 2024
A panel of experts shares their insights on key developments and advances in lung cancer treatment research.
Millie Das, MDASCO 2024 | August 6, 2024
An expert panel discusses treatment and quality-of-life considerations, as well as what to do while awaiting NGS results.
Millie Das, MDASCO 2024 | August 6, 2024
The panel discusses combination therapies and treatment considerations for patients without targetable mutations.
Millie Das, MDASCO 2024 | August 6, 2024
Experts weigh in on unmet needs and what clinicians should consider when treating patients who lack driver mutations.
Millie Das, MDASCO 2024 | August 6, 2024
Experts weigh in on NSCLC screening and diagnostic challenges and the prevalence of metastatic disease at diagnosis.